David E. Gilham

5.0k citations

90 papers · 3.7k indexed · h-index 35

Oncology top 0.5%
- CAR-T cell therapy research 77
- Cancer Immunotherapy and Biomarkers 8
Immunology top 1%
- Immune Cell Function and Interaction 35
- Immunotherapy and Immune Responses 26
- T-cell and B-cell Immunology 14
Genetics top 2%
- Virus-based gene therapy research 17
Biomedical Engineering top 5%
- Nanowire Synthesis and Applications 9
Molecular Biology top 10%
- Viral Infectious Diseases and Gene Expression in Insects 16

Co-authors: Robert E. Hawkins Eleanor J. Cheadle John S. Bridgeman Hinrich Abken Dominic G. Rothwell Peter L. Stern Н. А. Кириллова Gray Kueberuwa
Cited by: Oncology Immunology Genetics
Journals: Cancer Immunology Immunotherapy (8 papers)The Journal of Immunology (5 papers)Journal of Immunotherapy (5 papers)
Partner nations: United Kingdom United States Belgium

In The Last Decade

David E. Gilham

90 papers receiving 3.6k citations

Peers

Countries citing papers authored by David E. Gilham

Since Specialization

Citations

This map shows the geographic impact of David E. Gilham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gilham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gilham more than expected).

Fields of papers citing papers by David E. Gilham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Gilham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gilham. The network helps show where David E. Gilham may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David E. Gilham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David E. Gilham Line = papers co-authored together David E. Gilham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth JCI Insight ·Xiaodong Zhuang,Federica Maione,Joseph Robinson,Michael D. Bentley,Baksho Kaul,Cynthia H. Ervin,G. K. Vallis,Elizabeth Jinks,Jonas Byström,P. Gabriele,E. Garibaldi,E. Delmastro,Zsuzsanna Nagy,David E. Gilham,Enrico Giraudo,Roy Bicknell,Steven P. Lee	2020	58
2	Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy Cytotherapy ·Joana Murad,Susanne H.C. Baumeister,Lillian Werner,Heather Daley,Hélène Trebeden‐Negre,Jake Reder,Charles L. Sentman,David E. Gilham,Frédéric Lehmann,Sarah Snykers,Marie-Louise Sentman,Terri K. Wade,Adam Schmucker,Michael W. Fanger,Glenn Dranoff,Jerome Ritz,Sarah Nikiforow	2018	46
3	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types BMJ Open ·Caroline Lonez,Bikash Verma,Alain Hendlisz,Philippe Aftimos,Ahmad Awada,Eric Van Den Neste,Patricio Capelo Pontón,Jean‐Pascal Machiels,Fanny Piette,Jason Brayer,David A. Sallman,Tessa Kerre,Kunle Odunsi,Marco L. Davila,David E. Gilham,Frédéric Lehmann	2017	42
4	CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo Journal for ImmunoTherapy of Cancer ·Gray Kueberuwa,Hannah Gornall,Erik Alcantar-Orozco,Jackson Silva da Rocha Segundo,吉桂林,Robert E. Hawkins,David E. Gilham	2017	17
5	CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity Molecular Therapy — Oncolytics ·Gray Kueberuwa,Masaru Shiozuka,Pil Joong LEE,Robert E. Hawkins,David E. Gilham	2017	135
6	Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015 Human Gene Therapy ·David E. Gilham,John Anderson,John S. Bridgeman,Robert E. Hawkins,Mark A. Exley,Hans J. Stauss,John Maher,Martin Pulé,Andrew K. Sewell,Gavin Bendle,Steven Lee,Waseem Qasim,Adrian J. Thrasher,Emma Morris	2015	15
7	Genetic Modification of Mouse Effector and Helper T Lymphocytes Expressing a Chimeric Antigen Receptor Methods in molecular biology ·Liza B. John,F. Mazzola,David E. Gilham,Phillip K. Darcy	2014	2
8	In vitroeffect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells Expert Opinion on Pharmacotherapy ·Abdul Samad A,David E. Gilham,Robert E. Hawkins,Eyad Elkord	2014	8
9	Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy Cancer Immunology Immunotherapy ·Fernanda Castro,Thomas Ernest Boston-Kemple,森丘保典,Hui‐Rong Jiang,Jan W. Drijfhout,Sumia Ali,Andrzej Rutkowski,Masaru Shiozuka,David E. Gilham,Peter L. Stern	2011	7
10	Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells The Journal of Immunology ·Eleanor J. Cheadle,Robert E. Hawkins,David Leflang,J Pi√©rard,Simon J. Dovedi,David E. Gilham	2010	61
11	The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex The Journal of Immunology ·John S. Bridgeman,Robert E. Hawkins,Steve Bagley,Martina Lietz,Mark Holland,David E. Gilham	2010	201
12	Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy Current Gene Therapy ·John S. Bridgeman,Robert E. Hawkins,Andreas Hombach,Hinrich Abken,David E. Gilham	2010	84
13	T regulatory cells in cancer: recent advances and therapeutic potential Expert Opinion on Biological Therapy ·Eyad Elkord,Erik Alcantar-Orozco,Simon J. Dovedi,Dat Q. Tran,Robert E. Hawkins,David E. Gilham	2010	90
14	O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy British Medical Bulletin ·D. L. Segal,T. D. Southgate,David E. Gilham,Geoffrey P. Margison	2008	99
15	Rapid high-performance liquid chromatographic analysis of adenovirus type 5 particles with a prototype anion-exchange analytical monolith column Journal of Chromatography A ·Robert J. Whitfield,Phillip R. Tiller,Miloš Barut,David E. Gilham,Mykola Liutkevich	2008	33
16	Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors The Journal of Immunology ·Hui‐Rong Jiang,David E. Gilham,森丘保典,Н. А. Кириллова,Robert E. Hawkins,Peter L. Stern	2006	24
17	Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo Gene Therapy ·Alireza Biglari,T. D. Southgate,LJ Fairbairn,David E. Gilham	2006	46
18	Vaccine and antibody-directed T cell tumour immunotherapy Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Said Dermime,David E. Gilham,David Shaw,Emma J. Davidson,HAMILTON CARROLL,Anne Armstrong,Robert E. Hawkins,Peter L. Stern	2004	64
19	T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches British Journal of Cancer ·Aali J. Sheen,David Sherlock,Joely J. Irlam,Robert E. Hawkins,David E. Gilham	2003	15
20	Functional High Level Expression of Cytochrome P450 CYP2D6 Using Baculoviral Expression Systems Archives of Biochemistry and Biophysics ·Mark J. I. Paine,David E. Gilham,Gordon C. K. Roberts,C. Roland Wolf	1996	31

About David E. Gilham

David E. Gilham is a scholar working on Oncology, Immunology and Genetics, having authored 90 papers that have together received 3.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (77 papers), Immune Cell Function and Interaction (35 papers), Immunotherapy and Immune Responses (26 papers), Virus-based gene therapy research (17 papers), Viral Infectious Diseases and Gene Expression in Insects (16 papers), T-cell and B-cell Immunology (14 papers), Nanowire Synthesis and Applications (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). The work is most often cited by research in Oncology (3.0k citations), Immunology (1.6k citations) and Genetics (808 citations). David E. Gilham has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Robert E. Hawkins, Eleanor J. Cheadle, John S. Bridgeman, Hinrich Abken, Dominic G. Rothwell, Peter L. Stern, Н. А. Кириллова, Gray Kueberuwa, Ryan D. Guest and Richard W. Griffiths. Their work appears in journals such as Cancer Immunology Immunotherapy, The Journal of Immunology, Journal of Immunotherapy, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact